未登录

M

Mark G. Currie

harvard university medical affiliates

H指数:69

被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FAAH inhibitor URB597 shows anti-hyperalgesic action and increases brain and intestinal tissues fatty acid amides in a model of CRF1 agonist mediated visceral hypersensitivity in male rats

NEUROGASTROENTEROLOGY AND MOTILITY

IF2.9

2024-09-300

OA

The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system

JOURNAL OF NEUROINFLAMMATION

IF10.1

2021-09-1817

OAAI

Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease A Randomized Placebo-Controlled Clinical Trial

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IF7.1

2020-12-1625

OA

Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY

IF3.4

2020-10-0115

OAAI

Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Diabetic Kidney Disease

IF7.5

2020-06-012

PRE

Metabolic Effects of Praliciguat, Empagliflozin, and Their Combination in Rats with Programmed Hypertension and Early Exposure to High-Fat Diet

IF7.5

2020-06-010

PRE

Praliciguat, a Clinical -Stage Soluble Guanylate Cyclase (sGC) Stimulator, Improved Oral Glucose and Lipid Handling and Slowed Diabetic Weight Loss in TALLYHO Mice

IF7.5

2020-06-010

PRE

IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Re flux Disease in a Randomized Trial

GASTROENTEROLOGY

IF25.1

2020-06-0133

OAAI

Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY

IF3.4

2020-01-0133

OAAI

An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension

IF10.2

2019-12-1923

OAAI

Praliciguat, a Clinical-Stage sGC Stimulator, Improves Insulin Sensitivity, Lipid Tolerance, and Energy Utilization in a Mouse Diet-Induced Obesity Model Housed at Thermoneutrality

IF7.5

2019-06-011

PRE

sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2019-05-1340

OAAI

Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis

利那洛肽治疗慢性特发性便秘和便秘型肠易激综合征的安全性和耐受性: 合并3期分析

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY

IF2.5

2019-02-1813

OAAI

High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan

NEUROGASTROENTEROLOGY AND MOTILITY

IF2.9

2018-10-2332

OAAI

A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan

NEUROGASTROENTEROLOGY AND MOTILITY

IF2.9

2018-08-2223

OAAI

Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study

NEUROGASTROENTEROLOGY AND MOTILITY

IF2.9

2018-08-0713

OAAI

Rapid Dose Escalation Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension

IF7.5

2018-07-011

PRE

Fourteen-Day Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension

IF7.5

2018-07-014

PRE

Praliciguat, a Clinical-Stage sGC Stimulator, Improved Glucose Tolerance and Insulin Sensitivity and Lowered Triglycerides in a Mouse Diet-Induced Obesity Model

IF7.5

2018-07-010

PRE

Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2018-06-0154

OAAI